Developer docs
API playgroundTry for free, no card

Search company profiles

Prolacta Bioscience

Full company profile

uuid0000d36

Namestring
Prolacta Bioscience
Legal namestring
Prolacta Bioscience, Inc.
Websiteurl
prolacta.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Prolacta Bioscience is a privately held life sciences company founded in 1999 and headquartered in Duarte, California, that develops and manufactures 100% human milk-based nutritional products for premature and critically ill infants in neonatal intensive care units (NICUs). The company's core technology is its patented vat pasteurization process, operated in what it describes as the world's first pharmaceutical-grade human milk processing facilities (two locations in California, including City of Industry), supplemented by DNA-matching donor verification modeled on plasma and blood industry standards. Its product portfolio includes Prolact+ H2MF (the original 100% human milk fortifier for extremely premature infants weighing under 1,250g), PreemieFort (the world's first human milk-based fortifier approved as a prescription drug in Japan), Surgifort (the first FDA-approved human milk-based fortifier for term infants recovering from gastroschisis surgery), Humavant (Australian market), and Prolact CR cream supplement.

Prolacta generates revenue through exclusive B2B sales to hospitals under prescription-only distribution, with more than 50% of US Level III/IV NICUs using its products as of 2024. Pricing is quote-based via hospital contracts; the company describes an approximately $10,000 incremental spend per infant over ~60 days of use, offset by roughly $8,167 in hospital cost savings through reduced complications such as necrotizing enterocolitis (NEC). The go-to-market model is enterprise field sales with multi-year contracts, complemented by full implementation services including clinical outcome identification, feeding protocol design, coding/billing/reimbursement support, and staff training. International distribution is channel-based, notably through the Clinigen Group partnership for Japan (Marketing Authorization Holder for PreemieFort) and regional partners for Australia.

The company has raised approximately $78 million in disclosed venture funding across multiple rounds since 2004, with notable participation from Health Evolution Partners, Essex Woodlands Healthcare Partners, Aisling Capital, Alta Partners, and DFJ Mercury. Prolacta has grown to over 300 employees and has supported nutritional care for 125,000+ premature and critically ill infants worldwide since 2007, supported by 30+ peer-reviewed clinical studies including the 2025 JASMINE randomized trial. The company holds FDA food manufacturer registration, state tissue banking licenses (California, New York, Maryland), and the world-first regulatory approvals for human milk-based fortifiers as both a prescription drug (Japan MHLW, late 2025) and a term-infant fortifier (US FDA, Feb 2025).

Short descriptiontext

Prolacta Bioscience is a private life sciences company that develops 100% human milk-based nutritional fortifiers for premature and critically ill infants in hospital NICUs, sold prescription-only to US hospitals with growing international distribution in Japan and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCity Of Industry, United States
HQ citystring
City Of Industry
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human milk fortifiers, neonatal nutrition products, donor milk processing, NICU infant formulas, premature infant nutrition
Industry3 codes
PRIMARYAFAKAKAJ
Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAHAHAE
Premature & Low-Birth-Weight Infant Formula Manufacturing
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAHAHAJ
Specialized Dairy Nutrition Base Powder & Premix Manufacturing (Vitamin/Mineral/Functional Premixes)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
NAICS code3 codes
  • Dairy Product Manufacturing3115
  • Dairy Product (except Frozen) Manufacturing31151
  • Dry, Condensed, and Evaporated Dairy Product Manufacturing311514
SIC code1 code
  • Dairy Products2020
Product category
Neonatal Nutritional Products
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Hospital Product Sales
TypeSubscription Recurring
Description

Prolacta sells its 100% human milk-based nutritional products exclusively to hospitals for use in NICU settings. Products are prescribed by neonatologists and administered in hospital settings. The company has achieved market penetration with over 50% of Level III/IV NICUs in the US using their products. Pricing is quote-based through hospital contracts.

prolacta.com
2International Distribution
TypeLicensing Royalties
Description

Products are distributed internationally through partnerships. Japan market access achieved through Clinigen Group as exclusive licensee and Marketing Authorization Holder. Products also distributed in Australia, Europe, and Middle East.

prnewswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prolact+ H2MF for extremely premature infants
ModelOtherBilling cadenceMulti-year contract
Notes

Prescription-only hospital product for infants weighing 500-1250g at birth. Hospital pays for product; parents pay deductible. Added cost approximately $10,000 for 60 days of use.

prolacta.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1PreemieFort
Description

100% human milk-based fortifier approved as prescription drug in Japan and used for vulnerable premature infants

prolacta.com
+4 more records
Core offering1 text field

Prolacta Bioscience manufactures and sells 100% human milk-based nutritional fortifiers and enteral products (Prolact+ H2MF, PreemieFort, Surgifort, Humavant, Prolact CR Cream) for premature and critically ill infants in NICU settings. The products are made from carefully screened donor breast milk processed in two pharmaceutical-grade manufacturing facilities using vat pasteurization and a patented manufacturing process that retains bioactive components. Products are sold exclusively to hospitals through prescription-based, neonatologist-administered distribution channels in the U.S., Japan, Australia, and other international markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 77% reduction in NEC odds for infants 500-1250g when fed human milk with Prolact+ H2MF vs cow milk-based fortifier
+5 more records
Product overview1 text field

Prolacta Bioscience offers a portfolio of 100% human milk-based nutritional products for premature and critically ill infants. The core product line includes PreemieFort Enteral Solution (prescription drug for VLBW infants in Japan), Surgifort (FDA-approved for term infants post-gastroschisis surgery), Humavant (for Australia/New Zealand markets), and Prolact+ H2MF (the original human milk fortifier for extremely premature infants). These products are used as part of an Exclusive Human Milk Diet (EHMD) protocol and are supplemented by Prolact CR Cream. All products are made from donor human milk and processed using vat pasteurization to ensure pathogen inactivation while preserving bioactive components.

Product and service5 records
1Prolact+ H2MF
CategoryHuman milk-based fortifier
Description

The first and only human milk fortifier made from 100% human milk for extremely premature infants weighing 2 pounds 12 ounces (1250 grams) or less at birth. A concentrated breast milk-based fortifier with added essential minerals, used in NICU settings as part of an Exclusive Human Milk Diet protocol. Designed for prescription use under neonatologist authority.

2PreemieFort Enteral Solution
CategoryHuman milk-based fortifier
Description

A 100% human milk-based nutritional fortifier for very low birth weight infants, infants with congenital gastrointestinal disorders, congenital heart diseases, and post-surgical recovery cases. It is the world's first human milk-based nutritional product to receive prescription drug status, achieved in Japan in 2025. Used in NICU settings as part of an Exclusive Human Milk Diet protocol.

3Surgifort
CategoryHuman milk-based fortifier
Description

The first and only 100% human milk-based fortifier approved by the US FDA for term infants with gastroschisis who have undergone corrective surgical procedures. Supports healing and growth during post-surgical recovery. Made from 100% donor breast milk with essential minerals. Used in NICU and pediatric surgical settings.

4Humavant
CategoryHuman milk-based fortifier
Description

100% human milk-based fortifiers available to hospitals in Australia and New Zealand as an alternative to cow milk-based nutritional fortifiers for premature infants. Used as part of the Exclusive Human Milk Diet (EHMD) protocol. Products comply with FSANZ regulation.

5Prolact CR Cream
CategoryHuman milk-based nutritional supplement
Description

Human milk cream supplement used as part of an Exclusive Human Milk Diet to improve growth outcomes and reduce NICU costs for preterm infants. Provides additional calories and nutrients for very low birth weight infants in NICU settings.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-19
Description

Clinigen K.K. serves as exclusive licensee and Marketing Authorization Holder for PreemieFort products in Japan. Partnership enabled world-first regulatory approval for human milk-based fortifiers as prescription drugs. Clinigen handles distribution and market access for Japan's specialized neonatal nutrition market.

Strategic tierMinorTypeOthers
Description

Charitable partnership through Helping Hands Milk Bank where Prolacta donates $1 to Susan G. Komen for every ounce of qualified breast milk collected. Donations exceeded $406,000 since 2010.

Strategic tierMinorTypeOthers
Description

Annual sponsorship through Milk for Wishes Milk Bank. Prolacta donates $1 per ounce of qualified breast milk collected. Total donations exceeded $61,000 since 2011 with minimum annual commitment of $30,000.

4International Breast Milk Project
Strategic tierMinorTypeOthers
Description

Partnership for international milk donations. Prolacta contributions exceeded $567,000 since 2007. Milk collected through IBMP Milk Bank is primarily shipped to Africa for infants suffering from HIV/AIDS, malnourishment, poverty and disease.

prolacta.com
5National Milk Bank
Strategic tierMinorTypeOthers
Description

Affiliate milk bank partner that recruits potential breast milk donors for Prolacta. Previously affiliated from 2006-2009; renewed exclusive agreement in September 2011.

prolacta.com
6Helping Hands Milk Bank
Strategic tierMinorTypeOthers
Description

Affiliate milk bank collecting breast milk from overproducing mothers. For every ounce donated through HHMB, $1 is donated to Susan G. Komen. Has facilitated over $75,000 in donations.

prolacta.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Abbott Nutrition (a division of Abbott Laboratories) is a direct competitor through its Similac human milk fortifier and extensive NICU nutritional portfolio. Both Prolacta and Abbott serve Level III/IV NICUs with fortification products, but Prolacta differentiates via 100% human milk vs. cow milk-based formulations.

TypeDirect peer
Description

Mead Johnson, owned by Reckitt, produces Enfamil human milk fortifier and preterm infant formulas — the principal cow milk-based alternative to Prolacta's products in US NICUs. Both compete for the same neonatal nutrition prescribing decisions and hospital contracts.

TypeBroad incumbent
Description

Nestlé Health Science offers a broad portfolio of specialized pediatric and preterm nutrition products (e.g., PreNAN, peptamen) and is a global incumbent in clinical nutrition. It competes with Prolacta at the hospital formulary level for NICU feeding protocols.

TypeBroad incumbent
Description

Danone's Nutricia division produces preterm and specialized infant nutrition products (e.g., Infatrini, Nutrilon) widely used in European NICUs. As a broad incumbent with global distribution, it is a comparable — though diversified — competitor in the neonatal nutrition space.

TypeEmerging player
Description

NeoKare is a UK-based human milk processing company producing 100% human milk-based nutritional products for preterm and sick infants in European hospitals. It overlaps with Prolacta's human milk-based positioning but operates regionally and at smaller scale.

TypeEmerging player
Description

Medolac Laboratories develops shelf-stable human milk products for neonatal and pediatric nutrition. It is one of the few for-profit competitors to Prolacta in donor human milk-based nutritional products, though its commercial scale has been historically limited.

7Perrigo Nutritionals
TypeBroad incumbent
Description

Perrigo produces store-brand and private-label infant formulas including preterm formulations distributed in US hospitals and retail. As a broad incumbent in value infant nutrition, it is a comparable player in NICU formula markets though it does not offer human milk-based fortifiers.

TypeOthers
Description

HMBANA is a non-profit network of donor human milk banks that supply pasteurized donor milk to NICUs. While not a direct competitor in fortified products, HMBANA banks supply raw material to Prolacta and represent the alternative donor milk pathway for hospitals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prolacta Bioscience

Neonatal Nutritional Productsprolacta.com

Prolacta Bioscience is a private life sciences company that develops 100% human milk-based nutritional fortifiers for premature and critically ill infants in hospital NICUs, sold prescription-only to US hospitals with growing international distribution in Japan and Australia.

What Prolacta Bioscience does

Prolacta Bioscience is a privately held life sciences company founded in 1999 and headquartered in Duarte, California, that develops and manufactures 100% human milk-based nutritional products for premature and critically ill infants in neonatal intensive care units (NICUs). The company's core technology is its patented vat pasteurization process, operated in what it describes as the world's first pharmaceutical-grade human milk processing facilities (two locations in California, including City of Industry), supplemented by DNA-matching donor verification modeled on plasma and blood industry standards. Its product portfolio includes Prolact+ H2MF (the original 100% human milk fortifier for extremely premature infants weighing under 1,250g), PreemieFort (the world's first human milk-based fortifier approved as a prescription drug in Japan), Surgifort (the first FDA-approved human milk-based fortifier for term infants recovering from gastroschisis surgery), Humavant (Australian market), and Prolact CR cream supplement.

Prolacta generates revenue through exclusive B2B sales to hospitals under prescription-only distribution, with more than 50% of US Level III/IV NICUs using its products as of 2024. Pricing is quote-based via hospital contracts; the company describes an approximately $10,000 incremental spend per infant over ~60 days of use, offset by roughly $8,167 in hospital cost savings through reduced complications such as necrotizing enterocolitis (NEC). The go-to-market model is enterprise field sales with multi-year contracts, complemented by full implementation services including clinical outcome identification, feeding protocol design, coding/billing/reimbursement support, and staff training. International distribution is channel-based, notably through the Clinigen Group partnership for Japan (Marketing Authorization Holder for PreemieFort) and regional partners for Australia.

The company has raised approximately $78 million in disclosed venture funding across multiple rounds since 2004, with notable participation from Health Evolution Partners, Essex Woodlands Healthcare Partners, Aisling Capital, Alta Partners, and DFJ Mercury. Prolacta has grown to over 300 employees and has supported nutritional care for 125,000+ premature and critically ill infants worldwide since 2007, supported by 30+ peer-reviewed clinical studies including the 2025 JASMINE randomized trial. The company holds FDA food manufacturer registration, state tissue banking licenses (California, New York, Maryland), and the world-first regulatory approvals for human milk-based fortifiers as both a prescription drug (Japan MHLW, late 2025) and a term-infant fortifier (US FDA, Feb 2025).

Prolacta Bioscience firmographics

Firmographics
Name
Prolacta Bioscience
Legal name
Prolacta Bioscience, Inc.
Website
https://prolacta.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
251–500 employees
Short description
Prolacta Bioscience is a private life sciences company that develops 100% human milk-based nutritional fortifiers for premature and critically ill infants in hospital NICUs, sold prescription-only to US hospitals with growing international distribution in Japan and Australia.
Ownership category
akta.pro rank

Prolacta Bioscience industry classification

Industry
Product category
Neonatal Nutritional Products
NAICS
Dairy Product Manufacturing (3115), Dairy Product (except Frozen) Manufacturing (31151), Dry, Condensed, and Evaporated Dairy Product Manufacturing (311514)
SIC
Dairy Products (2020)
akta.pro industry
PRIMARYAFAKAKAJ
Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAHAHAE
Premature & Low-Birth-Weight Infant Formula Manufacturing
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAHAHAJ
Specialized Dairy Nutrition Base Powder & Premix Manufacturing (Vitamin/Mineral/Functional Premixes)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing

Keywords

  • Human milk fortifiers
  • Neonatal nutrition products
  • Donor milk processing
  • NICU infant formulas
  • Premature infant nutrition

Where Prolacta Bioscience is headquartered

Location

Headquarters

HQ city
City Of Industry
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Prolacta Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Hospital Product Sales: Prolacta sells its 100% human milk-based nutritional products exclusively to hospitals for use in NICU settings. Products are prescribed by neonatologists and administered in hospital settings. The company has achieved market penetration with over 50% of Level III/IV NICUs in the US using their products. Pricing is quote-based through hospital contracts.
  2. International Distribution: Products are distributed internationally through partnerships. Japan market access achieved through Clinigen Group as exclusive licensee and Marketing Authorization Holder. Products also distributed in Australia, Europe, and Middle East.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProlact+ H2MF for extremely premature infants

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Prolacta Bioscience product offering

Product offering

Core offering

Prolacta Bioscience manufactures and sells 100% human milk-based nutritional fortifiers and enteral products (Prolact+ H2MF, PreemieFort, Surgifort, Humavant, Prolact CR Cream) for premature and critically ill infants in NICU settings. The products are made from carefully screened donor breast milk processed in two pharmaceutical-grade manufacturing facilities using vat pasteurization and a patented manufacturing process that retains bioactive components. Products are sold exclusively to hospitals through prescription-based, neonatologist-administered distribution channels in the U.S., Japan, Australia, and other international markets.

Product overview

Prolacta Bioscience offers a portfolio of 100% human milk-based nutritional products for premature and critically ill infants. The core product line includes PreemieFort Enteral Solution (prescription drug for VLBW infants in Japan), Surgifort (FDA-approved for term infants post-gastroschisis surgery), Humavant (for Australia/New Zealand markets), and Prolact+ H2MF (the original human milk fortifier for extremely premature infants). These products are used as part of an Exclusive Human Milk Diet (EHMD) protocol and are supplemented by Prolact CR Cream. All products are made from donor human milk and processed using vat pasteurization to ensure pathogen inactivation while preserving bioactive components.

Differentiator

Problem solved

Functional benefit

Brands

  • PreemieFort: 100% human milk-based fortifier approved as prescription drug in Japan and used for vulnerable premature infants
  • Humavant
  • Surgifort
  • Prolact+ H2MF
  • Prolact CR

Products and services

  • Prolact+ H2MF The first and only human milk fortifier made from 100% human milk for extremely premature infants weighing 2 pounds 12 ounces (1250 grams) or less at birth. A concentrated breast milk-based fortifier with added essential minerals, used in NICU settings as part of an Exclusive Human Milk Diet protocol. Designed for prescription use under neonatologist authority.
  • PreemieFort Enteral Solution A 100% human milk-based nutritional fortifier for very low birth weight infants, infants with congenital gastrointestinal disorders, congenital heart diseases, and post-surgical recovery cases. It is the world's first human milk-based nutritional product to receive prescription drug status, achieved in Japan in 2025. Used in NICU settings as part of an Exclusive Human Milk Diet protocol.
  • Surgifort The first and only 100% human milk-based fortifier approved by the US FDA for term infants with gastroschisis who have undergone corrective surgical procedures. Supports healing and growth during post-surgical recovery. Made from 100% donor breast milk with essential minerals. Used in NICU and pediatric surgical settings.
  • Humavant 100% human milk-based fortifiers available to hospitals in Australia and New Zealand as an alternative to cow milk-based nutritional fortifiers for premature infants. Used as part of the Exclusive Human Milk Diet (EHMD) protocol. Products comply with FSANZ regulation.
  • Prolact CR Cream Human milk cream supplement used as part of an Exclusive Human Milk Diet to improve growth outcomes and reduce NICU costs for preterm infants. Provides additional calories and nutrients for very low birth weight infants in NICU settings.

Quantifiable outcome

  • 77% reduction in NEC odds for infants 500-1250g when fed human milk with Prolact+ H2MF vs cow milk-based fortifier
  • +5 more outcomes

Companies that use Prolacta Bioscience

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Prolacta Bioscience technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Prolacta Bioscience partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Clinigen GroupcoreChannel Partner/ Reseller/ Distributor · 19 February 2025Clinigen K.K. serves as exclusive licensee and Marketing Authorization Holder for PreemieFort products in Japan. Partnership enabled world-first regulatory approval for human milk-based fortifiers as prescription drugs. Clinigen handles distribution and market access for Japan's specialized neonatal nutrition market.
  • Susan G. Komen for the CureminorOthersCharitable partnership through Helping Hands Milk Bank where Prolacta donates $1 to Susan G. Komen for every ounce of qualified breast milk collected. Donations exceeded $406,000 since 2010.
  • Make-A-WishminorOthersAnnual sponsorship through Milk for Wishes Milk Bank. Prolacta donates $1 per ounce of qualified breast milk collected. Total donations exceeded $61,000 since 2011 with minimum annual commitment of $30,000.
  • International Breast Milk ProjectminorOthersPartnership for international milk donations. Prolacta contributions exceeded $567,000 since 2007. Milk collected through IBMP Milk Bank is primarily shipped to Africa for infants suffering from HIV/AIDS, malnourishment, poverty and disease.
  • National Milk BankminorOthersAffiliate milk bank partner that recruits potential breast milk donors for Prolacta. Previously affiliated from 2006-2009; renewed exclusive agreement in September 2011.
  • Helping Hands Milk BankminorOthersAffiliate milk bank collecting breast milk from overproducing mothers. For every ounce donated through HHMB, $1 is donated to Susan G. Komen. Has facilitated over $75,000 in donations.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Prolacta Bioscience competitors and assessment

Company assessment

Direct peers

  • Abbott Nutrition: Abbott Nutrition (a division of Abbott Laboratories) is a direct competitor through its Similac human milk fortifier and extensive NICU nutritional portfolio. Both Prolacta and Abbott serve Level III/IV NICUs with fortification products, but Prolacta differentiates via 100% human milk vs. cow milk-based formulations.
  • Mead Johnson Nutrition (Reckitt): Mead Johnson, owned by Reckitt, produces Enfamil human milk fortifier and preterm infant formulas — the principal cow milk-based alternative to Prolacta's products in US NICUs. Both compete for the same neonatal nutrition prescribing decisions and hospital contracts.

Broad incumbents

  • Nestlé Health Science: Nestlé Health Science offers a broad portfolio of specialized pediatric and preterm nutrition products (e.g., PreNAN, peptamen) and is a global incumbent in clinical nutrition. It competes with Prolacta at the hospital formulary level for NICU feeding protocols.
  • Danone Nutricia: Danone's Nutricia division produces preterm and specialized infant nutrition products (e.g., Infatrini, Nutrilon) widely used in European NICUs. As a broad incumbent with global distribution, it is a comparable — though diversified — competitor in the neonatal nutrition space.
  • Perrigo Nutritionals: Perrigo produces store-brand and private-label infant formulas including preterm formulations distributed in US hospitals and retail. As a broad incumbent in value infant nutrition, it is a comparable player in NICU formula markets though it does not offer human milk-based fortifiers.

Emerging players

  • NeoKare: NeoKare is a UK-based human milk processing company producing 100% human milk-based nutritional products for preterm and sick infants in European hospitals. It overlaps with Prolacta's human milk-based positioning but operates regionally and at smaller scale.
  • Medolac Laboratories: Medolac Laboratories develops shelf-stable human milk products for neonatal and pediatric nutrition. It is one of the few for-profit competitors to Prolacta in donor human milk-based nutritional products, though its commercial scale has been historically limited.

Others

  • Human Milk Banking Association of North America (HMBANA): HMBANA is a non-profit network of donor human milk banks that supply pasteurized donor milk to NICUs. While not a direct competitor in fortified products, HMBANA banks supply raw material to Prolacta and represent the alternative donor milk pathway for hospitals.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Prolacta Bioscience social profiles

Digital presence

Prolacta Bioscience compliance and trust

Trust signal

Compliance2 records

Prolacta Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prolacta Bioscience leadership team

Management profile

Number of profiles

Profiles15 records

Prolacta Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Prolacta Bioscience funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prolacta Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prolacta Bioscience

What does Prolacta Bioscience do?

Prolacta Bioscience manufactures and sells 100% human milk-based nutritional fortifiers and enteral products (Prolact+ H2MF, PreemieFort, Surgifort, Humavant, Prolact CR Cream) for premature and critically ill infants in NICU settings. The products are made from carefully screened donor breast milk processed in two pharmaceutical-grade manufacturing facilities using vat pasteurization and a patented manufacturing process that retains bioactive components. Products are sold exclusively to hospitals through prescription-based, neonatologist-administered distribution channels in the U.S., Japan, Australia, and other international markets.

Is Prolacta Bioscience a public or private company?

Prolacta Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prolacta Bioscience founded?

Prolacta Bioscience was founded in 1999. It employs 251 to 500 people.

Where is Prolacta Bioscience based?

Prolacta Bioscience is headquartered in City Of Industry, United States, in the North America region.

How does Prolacta Bioscience make money?

Two revenue lines are on record. Hospital Product Sales are the primary driver. The others are international Distribution.

Who are Prolacta Bioscience's main competitors?

Direct peers on record are Abbott Nutrition and Mead Johnson Nutrition (Reckitt). Broad incumbents are Nestlé Health Science, Danone Nutricia and Perrigo Nutritionals. Emerging players are NeoKare and Medolac Laboratories. Human Milk Banking Association of North America (HMBANA) is listed as an others.

Does Prolacta Bioscience have an API?

No public API is recorded for Prolacta Bioscience.

What industry is Prolacta Bioscience in?

Prolacta Bioscience's product category is Neonatal Nutritional Products. Its primary akta.pro industry code is AFAKAKAJ, Infant Formula & Specialized Dairy Nutrition Manufacturing, with a secondary code of AFAHAHAE, Premature & Low-Birth-Weight Infant Formula Manufacturing. Its NAICS code is 3115 and its SIC code is 2020.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire65% of U.S. Parents Surveyed Think "Human Milk Fortifier" Contains Donor Human Milk; Yet Only One DoesA Prolacta Bioscience survey of 1,000 U.S. parents found 65% believe human milk fortifier contains donor breastmilk, though only one U.S. product does. The company's donor-milk-based fortifier is used in over half of Level III and IV NICUs, and Japan granted it prescription drug status in December 2025.PR Newswire20 Years Advancing NICU Nutrition and Improving Outcomes for Babies Under 3 PoundsProlacta Bioscience marks NICU Awareness Month and 20 years of providing 100% breastmilk-based fortifiers for babies under 3 pounds. A study of over 1,000 premature infants found those on an exclusive human milk diet were less likely to have motor skill delays at age 3. Japan granted prescription drug status to its PreemieFort fortifiers in late 2025.PR NewswireJASMINE Trial Demonstrates Prolacta's Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan's Renowned Low NEC RateThe JASMINE randomized clinical trial published in the Journal of Perinatology evaluated Prolacta Bioscience's 100% human milk-based fortifiers against Japan's standard practice of delaying cow milk-based fortifiers for extremely premature infants across 11 Japanese NICUs. The trial found significantly faster weight gain (14.30 vs 11.96 g/kg/day, p < 0.0001) and earlier achievement of full feeds (20.0 vs 25.9 days) while maintaining Japan's low NEC rate under 2%. Japan's Ministry of Health, Labour, and Welfare used these findings to grant Prolacta's PreemieFort fortifiers prescription drug status in late 2025, making them the first human milk-based nutritional products to receive drug-level designation anywhere in the world.PharmExecFDA Approves Prolacta Bioscience’s Surgifort for Infants Recovering from Gastroschisis SurgeryThe FDA approved Prolacta Bioscience's Surgifort, the first human milk-based fortifier for term infants recovering from gastroschisis surgery. Clinical data showed it improved weight gain by 33.3 g/day and reduced time to full feeds. The company says it addresses an unmet need in neonatal nutrition.In VivoHow Clinigen Steered Prolacta’s Human Milk-Based Fortifier To Rx Medicine Approval In JapanClinigen, a pharma services company, successfully navigated Japan's PMDA regulatory framework to secure the first-ever global approval for Prolacta Bioscience's human milk-based fortifier (PreemieFort Enteral Solution) as a prescription biological product. The CEO highlighted the strong ongoing interface with Japan's regulator as key to defining a pathway where none previously existed. This approval enables Prolacta's premature infant nutrition product to enter the Japanese prescription pharmaceutical market.PR NewswireUne première mondiale en soins néonatals : le Japon approuve les fortifiants 100 % à base de lait humain de Prolacta Bioscience en tant que médicament sur ordonnance pour les nourissons vulnérablesJapan's Ministry of Health, Labour and Welfare (MHLW) has granted world-first regulatory approval for Prolacta Bioscience's PreemieFort, a 100% human milk-based fortifier, as a prescription drug for vulnerable infants in neonatal intensive care units. The approval, based on Phase III clinical data from the JASMINE trial submitted to Japan's PMDA, establishes human milk fortifiers as a regulated pharmaceutical product rather than a nutritional supplement, creating a precedent for NICUs globally. Clinigen Group served as the marketing authorization holder and distributor for the Japanese market.PR NewswireEine Weltneuheit in der Neugeborenenpflege: Japan genehmigt die zu 100 % aus Muttermilch hergestellten Nahrungsergänzungsmittel von Prolacta Bioscience als verschreibungspflichtiges Medikament für gefJapan's Ministry of Health, Labor and Welfare (MHLW) has approved Prolacta Bioscience's PreemieFort® Enteral Solution, a 100% human milk-based nutritional supplement, as a prescription drug for vulnerable infants including very low birth weight infants, infants with congenital gastrointestinal or heart conditions, and infants recovering from gastrointestinal surgery. The approval, achieved in collaboration with Clinigen Group and based on the JASMINE clinical study showing significantly better growth outcomes in very low birth weight infants without changes in morbidity or mortality, makes Japan the first country to grant prescription drug status to human milk-based fortifiers. This landmark regulatory decision establishes a precedent for human milk-based nutrition in neonatal intensive care units worldwide.PR NewswireJapón aprueba los fortificantes de Prolacta Bioscience, elaborados 100% con leche maternaJapan has approved Prolacta Bioscience's PreemieFort, a 100% human milk-based fortifier, as a prescription medication for vulnerable infants, marking a significant regulatory milestone. The approval was based on clinical trials leading to the validation of the benefits and safety of the product, which supports growth and health in preemies with complex needs.PR NewswireA World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable InfantsJapan's Ministry of Health, Labour and Welfare (MHLW) has approved Prolacta Bioscience's PreemieFort® Enteral Solution as a prescription drug for very low birth weight infants and those with congenital gastrointestinal or heart disorders, marking the world's first regulatory approval for 100% human milk-based fortifiers as an Rx medicine in the NICU. The approval, informed by clinical evidence from the Japanese-led JASMINE phase III trial, covers three Prolacta products and was achieved in partnership with Clinigen Group as Marketing Authorization Holder and distributor. This milestone positions human milk-based fortifiers as pharmaceutical-grade therapies rather than merely nutritional choices, setting a precedent for neonatal intensive care units worldwide.